Real Experts. Real Trades. Real Profits
It may seem counterintuitive given everything happening in the world at the moment, but we’ve actually had a few really good days in the market! Just look at the last three trading sessions of SPY: A strong rebound, with solid and healthy intraday volatility! The...
I usually say that major global events, however dramatic they may be, often present some of the best opportunities for us, traders… Whether we like it or not, this is one of the more cynical realities of this job - at times, traders thrive when others suffer....
If you haven’t been paying attention to the small-cap land, here’s one name that’s turned some heads over the past few sessions - Ocugen (OCGN). What began as a promising ripper, driven by a solid news catalyst: … turned into a disaster last night, as the company...
I know one word you haven’t heard in a while… crypto! With the sluggish performance of major coins and the general market calamities, traders simply haven’t had many reasons to follow the crypto world lately. But to somebody like Jason Bond, that only gives more...
The stock market is a competitive place… and if you’re a trader, you should aim to collect as much info as you humanly (and “machine-ly”) can. After all, knowing more than others or knowing it quicker may offer you an invaluable advantage. Seriously, we don’t even...
I asked everyone if they were excited about my Mission to Million. Feedback FLOODED in! I guess that’s what you can expect when a 20+ year pro trader launches the most significant journey of his career. This isn’t some “take the money and run” gimmick. I’m here for...
Good day, 360! Here are some of our top movers today. And don’t forget to join us for Mission to Million 🚀- happening 1pm EST. Get excited about our brand new member trading challenge (revealed today!). Please register here. FOCUS LIST🔎 VSTE – Up over 90%...
As we dive into the world of medical technology, one company that’s caught my attention is Bioventus (BVS). This Durham-based firm has been making waves in the industry with its innovative orthobiologic products for treating musculoskeletal conditions. And...
In a major breakthrough for the medical community, Mineralys Therapeutics has announced positive topline results from its pivotal Launch-HTN and Advance-HTN trials evaluating the efficacy and safety of lorundrostat for treating uncontrolled hypertension (uHTN) or...
In a move that’s sending shockwaves through the real estate industry, Redfin (RDFN) has announced it will be acquired by Rocket Companies in an all-stock deal worth $1.75 billion. The acquisition values Redfin at $12.50 per share, representing a whopping 63%...